Advancement of BIIB147, an Antisense Oligonucleotide Designed to Correct STMN2 Splicing, to a First-in-Human Phase 1/2 Study in ALS (NEALS 2026) - Oct 23, 2026 - Abstract #184; Pres time: Oct 29, 2026; 04:50 PM - 06:30 PM; Location: (Opal Sands) Ballroom; No abstract available
First-in-human • P1/2 data • STMN2
|